PFE performed quite well compared to its peers, and diversified companies like ABT and JNJ did very well too but foreign pharmas really shone. Here is a summary and the figures are approximate (for the last 52 weeks).
BMY rose only 6% and the dividend yield is 4.4%
MRK rose 11% and the yield is 4.2%
JNJ rose 14% and the yield is 3.5%
PFE rose 21% and the yield is 3.9%
ABT rose 22% and the yield is only .9%
NVS rose 24% and the yield is 3.9% like PFE
Roche, the Swiss giant (RHHBY) rose 30% but I am not sure about the dividend if they pay annualy or quarterly?
Now the Eliquis has been approved earlier than anticipated, I would expect analysts to increase PFE's earnings progections for the coming year. Apparently they will be able to advertise their new drug as superior to Warfarin, which their competitors can't do. PFE will make its move in due time. Good luck and Happy New Year!